CTIS2024-512903-38-00进行中（未招募）1 期
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 153
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age 18 years or older., Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1., Relapsed or refractory CD19-positive B-ALL, Patients with Philadelphia chromosome positive ALL (Ph+ ALL) are eligible if they are intolerant to or have failed two lines of any tyrosine kinase inhibitor (TKI) or one line of second-generation TKI, or if TKI therapy is contraindicated., In patients treated with blinatumomab, CD19 expression should be confirmed after blinatumomab therapy has been stopped., Adequate renal, hepatic, pulmonary, and cardiac function
排除标准
- •Diagnosis of Burkitt’s leukaemia/lymphoma according to World Health Organisation (WHO) classification or chronic myelogenous leukaemia lymphoid in blast crisis., History or presence of clinically relevant CNS pathology, Presence of CNS 3 disease or CNS 2 disease with neurological changes, Active or latent Hepatitis B or active Hepatitis C.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate AUTO1 in adults with Acute Lymphoblastic Leukaemia who have previously been treated and subsequently progressed.Relapsed or refractory B cell acute lymphoblastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864EUCTR2019-001937-16-GBAutolus Limited185
进行中（未招募）
1 期
A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion - Intraprostatic PRX302 injection to treat localised prostate cancerMedDRA version: 19.0Level: HLTClassification code 10036966Term: Prostatic neoplasms and hypertrophySystem Organ Class: 100000004872Prostate cancerEUCTR2016-004694-41-GBSophiris Bio Corp. 1258 Prospect Street La Jolla, CA 92037 USA40
招募中
1 期
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab, Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s LymphomaRelapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)MedDRA version: 25.0Level: LLTClassification code: 10086815Term: B-cell non-Hodgkin´s lymphoma recurrent Class: 100000004848MedDRA version: 25.0Level: LLTClassification code: 10086816Term: B-cell non-Hodgkin´s lymphoma refractory Class: 100000004848CTIS2023-505625-14-00F. Hoffmann-La Roche AG576
进行中（未招募）
1 期
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutatioPreviously Untreated Advanced NSCLC Harboring KRAS G12C MutationMedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864CTIS2022-501451-87-00Zhejiang Genfleet Therapeutics Co. Ltd.32
进行中（未招募）
1 期
Study of MEDI4736, when used in combination with chemotherapy agents or AZD5069, as first or second line in metastatic Pancreatic Ductal AdenocarcinomaEUCTR2015-003639-37-GBAstraZeneca AB27